Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- CVNA +8.1%, SEAC +7%, KEYS +6%, HOME +1.3%
M&A news:
- SAN +1.6% (to purchase Banco Popular Espanol SA)
Other news:
- DRWI +58% (awarded contract from SmartSky Networks, a North American 4G LTE inflight service provider)
- NNVC +37.8% (reports 'excellent' inhibitory effects of its topical shingles treatment candidates against VZV in multiple cell culture studies)
- WINS +7.7% (after more than doubling share price yesterday - closed up 107%)
- NVAX +4.9% (announces that data from the second of two Phase 2 trials of its RSV F protein recombinant nanoparticle vaccine candidate)
- CTIC +4.6% (modestly rebounding following following yesterday's decline)
- DVAX +4.3% (Point72 Asset Management increases passive stake )
- PLX +4.2% (will present phase II trial results for alidornase alfa (PRX-110) for the treatment of Cystic Fibrosis)
- AMD +3.4% (continued strength)
- GRAM +3.4% (sells stake in GMD)
- EGLT +3.3% (partners w/ Ascend Therapeutics to co-promote SPRIX Nasal Spray to more than 9,000 women's healthcare practitioners)
- HA +2.2% (reports May 2017 traffic statistics with RPMs +8%, ASMs +5% and load factor +2.4 pts; sees Q2 Operating Revenue Per ASM +7.5-10.5%, prior +5.5-8.5%)
- DXCM +1.2% (announces FDA approval of the Dexcom G5 mobile app for Android devices)
- HOLX +1.2% (FDA has approved co's Genius 3D Mammography exam), .
Analyst comments:
- CTSO +3.8% (initiated with a Outperform at Cowen; tgt $7)
- RBS +2.6% (upgraded to Hold from Sell at Investec)
- ORA +1.6% (upgraded to Overweight from Neutral at JP Morgan)
- LPNT +0.9% (upgraded to Outperform from Mkt Perform at Leerink Partners)
- DPS +0.5% (upgraded to Outperform from Market Perform at BMO Capital)